Sign in with Google
bullish
Dr Lal PathLabs Ltd (DLPL IN): Volume Driven Topline Growth and Margin Improvement Continued in Q2
361 Views24 Oct 2024 14:21
SUMMARY
- Dr Lal PathLabs Ltd (DLPL IN) reported 10% revenue growth in Q2, driven by volume. The bottomline surge of 18% has again outpaced revenue growth, resulting in margin expansion.
- There has been a significant improvement in Suburban’s revenue growth rate at 12%, with EBITDA margin reaching 20%. The company maintained 10% revenue growth target for the current financial year.
- The operating environment is becoming conducive. Competitive intensity in terms of predatory pricing, promotional offer, and cash burning to acquire customers, have come to an end.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- HEW: Poorly Positioned Doves
- Tam Jai (2217 HK): Toridoll (3397 JP)'s Excellent Offer. Still.
- STTF Index Rebalance: Keppel DC REIT Replaces Jardine Cycle & Carriage
- Great Eastern (GE SP): OCBC Bumps Terms - $30.15/Share Exit Offer
- Event-Driven Optionality in ProSieben: Playing the Floor, Targeting the Upside
Top Unpaywalled Insights
More »- [IO Technicals 2025/23] Bearish Momentum Persists
- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
- [IO Technicals 2025/22] Bearish Momentum Strengthens
- Texas Power Play: Grid Sovereignty, Bitcoin, and the Future of AI
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Dr Lal PathLabs Ltd (DLPL IN): Volume Driven Topline Growth and Margin Improvement Continued in Q224 Oct 2024
- Dr Lal PathLabs Ltd (DLPL IN): Poised for Next Level of Growth Amid Easing Price Competition02 Oct 2024
- Dr Lal PathLabs (DLPL IN): Strong Trajectory in Non-COVID Business; Positive Industry Outlook11 Jul 2023
- Dr Lal PathLabs (DLPL IN): Losing Path Amid Competition; Non-COVID Growth Underwhelming30 Mar 2023
x